Publications

I’m sure we’d all hoped that this year would be a return to normal but, in the midst of the challenges we’ve faced with COVID-19, the rheumatology community has continued to deliver excellent publications, and we’ve covered many of these on the CSF. Here are my highlights from 2021's publications:

• Points to Consider for the Treatment of Immune-Mediated Inflammatory Diseases With Janus Kinase Inhibitors: A Consensus Statement Nash P et al.
• Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate Westhovens R et al.
• Filgotinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate Combe B et al.
• Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors Aletaha D et al.
• Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years Winthrop KL et al.
• JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib Traves PG et al.
• Upadacitinib for psoriatic arthritis refractory to biologics Mease PJ et al.
• Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study Mease PJ et al.
• Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis McInnes IB et al.
• Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Rheumatoid Arthritis Strand V et al.
• Tofacitinib in juvenile idiopathic arthritis Ruperto N et al.
• Median Time to Pain Improvement and the Impact of Baseline Pain Severity on Pain Response in Patients with Psoriatic Arthritis Treated with Tofacitinib de Vlam K et al.
• Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice Miyazaki Y et al.
• Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis van der Heijde D et al.
• Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis Sparks JA et al.

  Keywords:

  • Review